• Record quarterly revenue of $9.5 million, up 204% on Q4 FY24 and 33% on Q3 FY25
• Record quarterly cash receipts of $10.7 million, up 302% on Q4 FY24 and 26% on Q3 FY25
• Unaudited FY25 revenue of $29.3 million, exceeding guidance by $1.3 million

Bioxyne Limited (ASX:BXN), an Australian life sciences, pharmaceutical and consumer health products company, has reported a strong Q4 FY25 trading performance, with a 33% increase on the prior quarter and a 204% increase on the prior year corresponding period. The company generated record quarterly revenue of $9.5 million and record quarterly cash receipts of $10.7 million, representing a 302% increase on Q4 FY24 and a 26% increase on Q3 FY25. Unaudited FY25 revenue of $29.3 million exceeded the company's revenue guidance of $28 million by $1.3 million. The company also generated positive operating cash flow of $1.5 million in the quarter, after investing further in working capital to support the significant growth of the business. Additional capex during the quarter was $0.3 million. The major contributor to the group's results is Breathe Life Sciences (BLS) Australia, the company's leading manufacturer and wholesaler of novel medicines, including cannabis, MDMA, and Psilocybin. The group continues to invest in the rapidly growing markets of the UK and Europe, which are anticipated to continue to drive top and bottom line growth into FY26.

The company expects to substantially exceed FY25 revenue performance in FY26.

The company is focused on growing its manufacturing customer base in Australia, the UK and Europe, gaining EU GMP certification in Czechia for distribution to European markets, and launching its medicinal cannabis products in the UK and European markets with local partners.